Dr. Izrael Joined Kadimastem in 2009. Prior to joining Kadimastem, as part of her doctoral work at the Weizmann Institute of Science in the laboratory of Prof. Revel, Dr. Izrael was a central part of the team that invented and developed the technology which became the basis for Kadimastem’s cell therapy product for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. At Kadimastem she served as the head of the drug screening team, based on human oligodendrocytes (Myeling forming cells), and in 2012 was appointed to run the neurodegenerative department at Kadimastem, responsible for Kadimastem’s cell product for ALS. In 2017 she was appointed as VP for Research and Development for ALS and Neurodegenerative Diseases. Dr. Izrael holds a PhD in molecular genetics from the Weizmann Institute of Science and M.Sc. in Neurobiology from the Hebrew University of Jerusalem. Dr. Izrael has published 16 scientific papers and patents in the field of neurobiology and development of technologies based on stem cell derivatives for the treatment of central nervous system disease and drug screening.
Archives: Speakers
Noorddin Taj
Noorddin serves as a Strategy, Architecture and Digital Innovation leader within BP; responsible for driving IT strategy, architecture, exploring new business models by emerging technologies (Blockchain, Machine Learning, IIOT, and Cloud). Noorddin has 20+ years of experience in Business Transformation, IT Strategy and Architecture, Mergers & Acquisition and for developing authentic relationship with customers to truly understand what drives them, and then crafting creative solution to their most critical problems. Noorddin has passion for emerging and innovative technologies and to successfully deploying them in program of works to improve, delivery and to generate maximum business value from technology investment. Noorddin holds an MBA in Strategic Management and MS in Industrial and Systems Engineering. He is Certified Project Management Professional (PMP) & Certified Architect (TOGAF). He has published articles on Pitfalls to avoid; on a journey to digital transformation and how to run successful IT program to support M&A Initiatives He is a frequent speaker at various conferences across US and Europe
Tony Edwards
CEO of Stepchange Global Limited, Tony has extensive experience in the oil and gas exploration and production industry worldwide. Tony has a BA degree from Keele University in Geology and Chemistry, and a Doctorate in Metamorphic Petrology from the University of Manchester. He had a 17 year career with BP that spanned R&D through to front line operations and project management. He was a founder member of BP’s Integrated Operations Program, Field of the Future, and was subsequently the global director for the Advanced Collaborative Environment Program that rolled out real time collaboration centers around the BP portfolio of assets. In 2006 he moved to BG-Group to launch its digital oilfield program under the name iValue. In January 2009 he co-founded Stepchange Global, a dedicated digital oilfield consultancy and advisory company, and has since advised Equinor, BP, PETRONAS, ConocoPhillips, Total, Santos, Origin Energy, Baker Hughes, HP, BHP Billiton, Emerson and BAE systems on their Integrated Operations strategies.
Tony is regarded as one of the key thought leaders in Digital Oilfield and Integrated Operations and has been active in both the SPE and EAGE. He was the chairman of the organising committee for the highly successful Intelligent Energy Conference in 2008, and is now on the SPE intelligent Energy committee for 2014. Tony was invited to sit on the SPE Annual Technical Conference Committee for 2011 and was Chairman of the Digital Energy Section.
Tony has written numerous papers on the subject of intelligent energy and collaborative working. The most recent paper was co-authored with Dr Anne Quaadgras of MIT.
Adar Shani
Michael Breen PhD
Angad Lotay (MPharm)
Marco Hogenboom
Frank Jaeger
Since March 2024, Frank Jäger has been leading the global business of CCL Clinical worldwide as Commercial Director worldwide, overseeing collaboration with the research-based pharmaceutical industry.
An economist by training, he has been part of the management team at CCL Faubel GmbH since 2014, where he is responsible for sales, marketing, label design, product development, and smart labels.
As a long-standing member of the International Society for Pharmaceutical Engineering (ISPE), he has delivered numerous presentations at trade shows and conferences, addressing specific challenges
related to the labeling and packaging of active ingredients and therapies. In 2024, he was appointed to the ISPE Steering Committee as a special honor.
Deb Kie
Deb Kientop
Deb Kientop, MBA brings over 25 years of experience in oncology drug development, starting in the cancer research labs at the University of Wisconsin, and moving into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, and corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Deb is also a published author and cancer patient advocate.
Prior to joining Synteract, Deb was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma, and Eisai.
Deb holds a Bachelor of Science in Pharmacology and Toxicology, and a Master of Business Administration from the University of Wisconsin.